Vivesto AB (OASMY)
0.0499
0.00 (0.00%)
USD |
OTCM |
Jun 28, 16:00
Vivesto Enterprise Value: 3.278M for June 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 28, 2024 | 3.278M |
| June 27, 2024 | 3.278M |
| June 26, 2024 | 3.278M |
| June 18, 2024 | 3.278M |
| June 17, 2024 | 3.278M |
| June 14, 2024 | 3.278M |
| June 13, 2024 | 3.278M |
| June 12, 2024 | 3.278M |
| June 11, 2024 | 3.278M |
| June 10, 2024 | 3.278M |
| June 07, 2024 | 3.278M |
| June 06, 2024 | 3.278M |
| June 05, 2024 | 3.278M |
| June 04, 2024 | 3.278M |
| June 03, 2024 | 3.278M |
| May 31, 2024 | 3.278M |
| May 30, 2024 | 3.278M |
| May 29, 2024 | 3.278M |
| May 28, 2024 | 3.278M |
| May 24, 2024 | 3.278M |
| May 23, 2024 | 3.278M |
| May 22, 2024 | 3.278M |
| May 21, 2024 | 3.278M |
| May 20, 2024 | 3.278M |
| May 17, 2024 | 3.278M |
| Date | Value |
|---|---|
| May 16, 2024 | 3.278M |
| May 15, 2024 | 3.278M |
| May 14, 2024 | 3.278M |
| May 13, 2024 | 3.278M |
| May 10, 2024 | 3.278M |
| May 09, 2024 | 3.278M |
| May 08, 2024 | 3.278M |
| May 07, 2024 | -2.084M |
| May 06, 2024 | -2.084M |
| May 03, 2024 | -2.084M |
| May 02, 2024 | -2.084M |
| May 01, 2024 | -2.084M |
| April 30, 2024 | -2.084M |
| April 29, 2024 | -2.084M |
| April 26, 2024 | -2.084M |
| April 25, 2024 | -2.084M |
| April 24, 2024 | -2.084M |
| April 23, 2024 | -2.084M |
| April 22, 2024 | -2.084M |
| April 19, 2024 | -2.084M |
| April 18, 2024 | -2.084M |
| April 17, 2024 | -2.084M |
| April 16, 2024 | -2.084M |
| April 15, 2024 | -2.084M |
| April 12, 2024 | -2.084M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.95M
Minimum
Oct 11 2022
350.30M
Maximum
Mar 25 2020
102.96M
Average
101.93M
Median
Sep 30 2021
Enterprise Value Benchmarks
| Abliva AB | 10.57M |
| Karolinska Development AB | 62.17M |
| Calliditas Therapeutics AB | 1.063B |
| Oncopeptides AB | 12.46M |
| Olink Holding AB | 3.059B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8119M |
| Total Expenses (Quarterly) | 0.8976M |
| EPS Diluted (Quarterly) | -0.0058 |
| Earnings Yield | -124.9% |
| Normalized Earnings Yield | -168.19 |